{3-[6-(4-hydroxy-3-methoxy-phenyl)-pyrazin-2-yl]-phenyl}-morpholin-4-yl-methanone | 1034296-49-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: {3-[6-(4-hydroxy-3-methoxy-phenyl)-pyrazin-2-yl]-phenyl}-morpholin-4-yl-methanone
• 英文别名: [3-[6-(4-Hydroxy-3-methoxyphenyl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone
• CAS: 1034296-49-5
• 化学式: C₂₂H₂₁N₃O₄
• 分子量: 391.426
• InChiKey: LVQCBZAISRFQSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  84.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS
  申请人：Raynham Tony Michael

  公开号：US20110098325A1

  公开（公告）日：2011-04-28

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyridine benzamide and pyrazine benzamide compounds (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

  本发明涉及治疗化合物领域，更具体地涉及某些吡啶苯甲酰胺和吡嗪苯甲酰胺化合物（以下简称PDBA和PZBA化合物），它们可以抑制蛋白激酶D（PKD）（例如PKD1、PKD2、PKD3）。本发明还涉及包含这些化合物的制药组合物，以及在体外和体内使用这些化合物和组合物来抑制PKD，在治疗由PKD介导、通过抑制PKD改善的疾病和病况，包括增生性疾病如癌症等。
• [EN] PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS<br/>[FR] BENZAMIDES DE PYRIDINE ET BENZAMIDES DE PYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PKD
  申请人：CANCER REC TECH LTD

  公开号：WO2008074997A1

  公开（公告）日：2008-06-26

  [EN] The present invention pertains generally to the field of therapeutic compounds,. arid more specifically to certain pyridine benzamide and pyrazine benzamide compounds (I) (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD1 that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
  [FR] La présente invention concerne en général le domaine des composés thérapeutiques, et plus spécifiquement certains composés benzamides de pyridine et benzamides de pyrazine (I) (désignés ici comme composés PDBA et PZBA) qui, entre autres, inhibent la protéine kinase D (PKD) (par exemple, la PKD1, la PKD2, la PKD3). La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés, et l'utilisation de tels composés et compositions, à la fois in vitro et in vivo, pour inhiber la PKD, et dans le traitement de maladies et conditions qui sont induites par la PKD1 qui sont améliorées par l'inhibition de la PKD, etc., y compris des conditions prolifératives telles que le cancer, etc.